Immune response is common across the field, and several trials show encouraging signals: multi-year survival follow-up, longer survival than matched controls in early glioblastoma data, and objective responses in melanoma. Making that durability consistent, trial to trial, is what better target selection is for.
This is the field's comparator evidence: published trial results from other groups' vaccine programs, researched to establish where the science already stands. See our FAQ page for where the company's own regulatory process stands today.
| Trial | Vaccine type | Personalized | Phase | Cancer type | Response | Read |
|---|---|---|---|---|---|---|
| PGV001 (Mount Sinai) | Peptide | Yes | Ph1 | Multiple cancers (adjuvant) | Immune response in all 11 patients who completed treatment; 6 of 13 alive at 5 years (3 cancer-free) | Peptide plus poly-ICLC; single arm |
| NeoVax (Dana-Farber) | Peptide | Yes | Ph1 | Glioblastoma | Median overall survival 36.9 vs 25.3 months (MGMT-methylated) and 19.0 vs 16.7 months (MGMT-unmethylated), versus matched controls | Peptide plus poly-ICLC, given with pembrolizumab; matched institutional controls, not randomized; conference abstract |
| GNOS-PV01 (Geneos) | DNA plasmid | Yes | Ph1 | Glioblastoma (MGMT-unmethylated) | 12-month overall survival 66.7% (6 of 9); median overall survival 16.3 months | Personalized DNA plasmid, not a peptide vaccine; single arm |
| EVX-01 (Evaxion) | Peptide | Yes | Ph1/2 | Melanoma | Phase 1: 67% objective response (8 of 12), including 2 complete responses. Phase 2: 75% (12 of 16), including 4 complete responses | Given with pembrolizumab; Phase 2 is company-reported, not yet peer reviewed |
| mRNA-4157 / V940 (Moderna, Merck) | mRNA | Yes | Ph2b | Melanoma (adjuvant) | 44% lower risk of recurrence or death at about 2 years (hazard ratio 0.56, 95% CI 0.31 to 1.02; 157 patients); 49% lower at 5 years | mRNA, not a peptide vaccine; the Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint, full results pending |
| iTAC-XS15-CLL01 (Tübingen) | Peptide | Yes | Ph1 | Chronic lymphocytic leukemia | T-cell response in 95% of patients (19 of 20); 84% sustained at 6 months (16 of 19) | Personalized peptides plus XS15 adjuvant, given with a BTK inhibitor; measured immune response, not efficacy |
| PolyPEPI1018 (Treos Bio) | Peptide | No | Ph1b | Colorectal cancer (MSS, metastatic) | 27% objective response (3 of 11); median progression-free survival 12.5 months with multiple doses (6 patients) vs 4.6 months with one dose (5 patients) | Off the shelf (7 shared antigens), given with maintenance chemotherapy |
| UCPVax (Besançon University Hospital) | Peptide | No | Ph2 | Glioblastoma (MGMT-unmethylated) | Anti-telomerase immune response in 97% (29 of 30); median overall survival 17.9 months (31 patients) | Off the shelf (shared telomerase antigen); single-arm first cohort; conference abstract |
PGV001 was run at the Icahn School of Medicine at Mount Sinai in New York. That is a separate institution from Mount Sinai Hospital, Toronto, the company's academic sequencing partner. See Team & Partners. The shared name is a coincidence worth flagging clearly.
Not every trial in this field succeeds. This page is meant to stay evidence based rather than cherry picked. The field has real, well documented setbacks alongside its wins, and that context matters.
See how NSP targets this gap